

STATE OF NEW HAMPSHIRE

SENATE

REPORT OF THE COMMITTEE FOR THE CONSENT CALENDAR

Thursday, February 12, 2026

THE COMMITTEE ON Health and Human Services

to which was referred **SB 477-FN**

AN ACT relative to increasing transparency in the 340B Drug Pricing Program.

Having considered the same, the committee recommends that the Bill

BE REFERRED TO INTERIM STUDY

BY A VOTE OF: 5-0

Senator Kevin Avard
For the Committee

This bill establishes certain reporting requirements for the Department of Health and Human Services, hospitals, and other covered entities participating in the 340B Drug Pricing Program. The bill also directs the Department to require claim-level 340B identifiers across fee-for-service and managed care organization claims and to implement exclusion rules to prevent duplicate discounts, consistent with GAO/CMS guidance. While the Committee appreciates the intent of increasing transparency, we feel it is best to recommend this bill for interim study because this is dealing with a federal program.

Sophie Walsh 271-3469

FOR THE CONSENT CALENDAR

HEALTH AND HUMAN SERVICES

SB 477-FN, relative to increasing transparency in the 340B Drug Pricing Program.

Interim Study, Vote 5-0.

Senator Kevin Avarad for the committee.

This bill establishes certain reporting requirements for the Department of Health and Human Services, hospitals, and other covered entities participating in the 340B Drug Pricing Program. The bill also directs the Department to require claim-level 340B identifiers across fee-for-service and managed care organization claims and to implement exclusion rules to prevent duplicate discounts, consistent with GAO/CMS guidance. While the Committee appreciates the intent of increasing transparency, we feel it is best to recommend this bill for interim study because this is dealing with a federal program.